Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience.

Nicolo Matteo Luca BattistiBelinda KingstonJudy KingArshi DentonSimon WatersAilsa Sita-LumsdenFarah RehmanChara StavrakaHartmut KristeleitElinor SawyerDavid HoughtonNeville DavidsonSacha HowellJulia ChoyPeter HarperRebecca RoylanceRaja FharatKabir MohammedAlistair RingStephen Johnston

Published in: Breast cancer research and treatment (2019)

This is the most extensive analysis of palbociclib in ≥ 4th-line setting. Clinical benefit was confirmed particularly for endocrine-sensitive, predominantly bony disease and in earlier lines of treatment. Safety was similar to PALOMA trials with higher febrile neutropenia rate.

Keyphrases

metastatic breast cancer
chemotherapy induced
cross sectional
randomized controlled trial
combination therapy
mesenchymal stem cells
african american
young adults